Key terms

About PEN

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest PEN news

Today 5:49am ET 3 Best Stocks to Buy Now, 4/16/2024, According to Top Analysts Apr 12 8:29am ET Piper Sandler Remains a Buy on Penumbra (PEN) Apr 03 7:10am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Mar 25 10:30pm ET Wall Street Analysts Are Bullish on Top Healthcare Picks Mar 22 9:30am ET Penumbra price target lowered to $280 from $290 at Truist Mar 22 9:28am ET Inari Medical price target lowered to $52 from $61 at Truist Mar 19 6:16am ET Positive Outlook for Penumbra: Accelerated THUNDER Trial Progress and Thunderbolt System Potential Justify Buy Rating Mar 01 5:04am ET Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX) Feb 25 11:35pm ET Buy Rating Justified by Penumbra’s Market Presence and Projected Growth Feb 23 9:47am ET Penumbra falls -9.2% Feb 23 9:25am ET Penumbra price target lowered to $290 from $300 at Truist Feb 23 8:31am ET Penumbra price target lowered to $290 from $310 at Piper Sandler Feb 23 7:51am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD) Feb 23 7:35am ET Maintaining Buy Rating on Penumbra: Strong Growth Prospects and Strategic Focus Feb 23 7:31am ET Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN) Feb 23 7:20am ET RBC Capital Remains a Buy on Penumbra (PEN) Feb 23 6:10am ET Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Penumbra (PEN) and BioMarin Pharmaceutical (BMRN) Feb 23 5:45am ET Hold Rating on Penumbra: Balancing Operational Strengths and Market Expectations Feb 23 5:08am ET Penumbra downgraded to Neutral from Overweight at JPMorgan Feb 22 4:09pm ET Penumbra sees FY24 revenue $1.23B-$1.27B, consensus $1.27B Feb 22 4:07pm ET Penumbra reports Q4 adjusted EPS 76c, consensus 70c Feb 06 5:37am ET Buy Rating Affirmed: Penumbra’s Strong Product Pipeline and Technological Advancements Set to Drive Growth Jan 30 9:25pm ET Truist Financial Remains a Buy on Penumbra (PEN) Jan 26 5:36am ET Wall Street Analysts Are Bullish on Top Healthcare Picks

No recent news articles are available for PEN

No recent press releases are available for PEN

PEN Financials

1-year income & revenue

Key terms

PEN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

PEN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms